ArticleFrontiers in pharmacology2021

Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors.

Jingrui Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.